SCHEDULE: Vanguard Group Adjusts Bristol-Myers Squibb Ownership Reporting
Beneficial Ownership Report
The Vanguard Group has amended its Schedule 13G filing for Bristol-Myers Squibb Co, reporting 0% beneficial ownership due to an internal realignment.
Summary
- The Vanguard Group filed an Amendment No. 10 to its Schedule 13G for Bristol-Myers Squibb Co.
- As of the filing, The Vanguard Group reports 0 shares and 0% beneficial ownership of Bristol-Myers Squibb Co. common stock.
- This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
- Following the realignment, certain subsidiaries or business divisions of Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis).
- The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral. It primarily reflects a procedural change in how The Vanguard Group reports its beneficial ownership due to an internal realignment, rather than a change in investment thesis regarding Bristol-Myers Squibb Co.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that large institutional investors like The Vanguard Group periodically undergo internal restructurings or realignments that impact how their holdings are reported to the SEC. This particular filing reflects a shift in reporting methodology rather than a strategic divestment from Bristol-Myers Squibb Co. by the broader Vanguard organization, as beneficial ownership will now be reported by disaggregated subsidiaries.
Stakeholder Impact
- Shareholders of Bristol-Myers Squibb Co. will see The Vanguard Group, Inc. itself report 0% beneficial ownership, but underlying holdings may still be present and reported by Vanguard's disaggregated subsidiaries.
Key Dates
| Date | Description |
|---|---|
| 01/12/2026 | Date of internal realignment within The Vanguard Group, Inc., leading to disaggregated reporting. |
| 03/13/2026 | Date of event which required the filing of this statement. |
| 03/26/2026 | Date the Schedule 13G/A was signed and filed. |
Keywords
Schedule 13G, Beneficial Ownership, Vanguard Group, Bristol-Myers Squibb, SEC Filing, Institutional Investor, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.